Renewed Interest in Ibritumomab for Non-Hodgkin's Lymphoma Medscape Before the new FDA ruling, the bioscan protocol required patients to receive an infusion of rituximab on day 1, which was followed by a diagnostic dose of radiolabeled indium-111 [ibritumomab tiuxetan] and a full-body scan at a nuclear imaging center ... |
